tradingkey.logo
tradingkey.logo
検索

Pfizer Inc

PFE
ウォッチリストに追加
27.960USD
-0.060-0.21%
終値 08-28 16:00ET
159.34B時価総額
21.23直近12ヶ月PER

詳細情報 Pfizer Inc 企業名

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Pfizer Inc プロフィール

企業コードPFE
会社名Pfizer Inc
上場日Feb 22, 2080
最高経営責任者「CEO」Bourla (Albert)
従業員数81000
証券種類Ordinary Share
決算期末Feb 22
本社所在地66 Hudson Boulevard East
都市NEW YORK
証券取引所NASDAQ OMX NASDAQ Basic NYSE
United States of America
郵便番号10001-2192
電話番号12127332323
ウェブサイトhttps://www.pfizer.com/
企業コードPFE
上場日Feb 22, 2080
最高経営責任者「CEO」Bourla (Albert)

Pfizer Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
+8.78%
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
+8.78%
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
+8.78%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+7.61%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
71.69K
+54.72%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
71.69K
+54.72%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
71.69K
+54.72%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
+8.78%
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
+8.78%
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
432.63K
+8.78%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
165.26K
+2.36%

よくある質問

Pfizer Incの上位5名の株主は誰ですか?

Pfizer Incの上位5名の株主は以下のとおりです。Dr. Albert Bourla, Ph.D.

Pfizer Inc(PFE)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Pfizer Incの株式を保有している機関は4824社あり、保有株式の総市場価値は約3.98Bで、全体の69.87%を占めています。2025Q4と比較して、機関の持ち株は29483336.00増加しています。

Pfizer Incの最大の収益源は何ですか?

2026Q1において、Eliquis alliance revenues and direct sales部門がPfizer Incにとって最大の収益を生み出しており、その金額は2.42Bで、全収益の16.13%を占めています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。